Richard R. Elliott

Edinburgh, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

High-throughput screening identifies the activity of histone deacetylase inhibitors in patient-derived models of soft tissue sarcoma.

High-throughput screening identifies the activity of histone deacetylase inhibitors in patient-derived models of soft tissue sarcoma.

Journal: Cancer biology & therapy

Published: November 30, 2025

High-throughput 3D phenotypic screening identifies repurposed MEK inhibitors as drivers of chondrogenesis for cartilage regeneration.

High-throughput 3D phenotypic screening identifies repurposed MEK inhibitors as drivers of chondrogenesis for cartilage regeneration.

Journal: Frontiers in bioengineering and biotechnology

Published: November 17, 2025

A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models.

A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models.

Journal: iScience

Published: August 20, 2025

Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Journal: Nature communications

Published: July 15, 2025

Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular models.

Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular models.

Journal: Digital discovery

Published: May 09, 2025

Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signaling.

Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signaling.

Journal: bioRxiv : the preprint server for biology

Published: April 08, 2025

Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma.

Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma.

Journal: Pharmaceutics

Published: March 06, 2025

Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Journal: Nature communications

Published: March 18, 2024

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

Journal: Nature communications

Published: March 18, 2024

High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.

High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.

Journal: Gynecologic oncology

Published: February 06, 2024

Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against glioblastoma cells.

Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against glioblastoma cells.

Journal: RSC medicinal chemistry

Published: August 30, 2023

A cautionary note on the use of N-acetylcysteine as a reactive oxygen species antagonist to assess copper mediated cell death.

A cautionary note on the use of N-acetylcysteine as a reactive oxygen species antagonist to assess copper mediated cell death.

Journal: PloS one

Published: July 31, 2023

Showing 1-12 of 34

Last Updated: 09/26/2026